Clear All
12250 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
67386-0411-51 67386-0411 Asparaginase (E. coli) Elspar Chemotherapy Miscellaneous Agent Enzyme Intramuscular Jan 10, 1978 Jul 18, 2013 No Longer Used
00024-5150-10 00024-5150 Rasburicase Elitek Ancillary Therapy Metabolic Agent Enzyme Jul 12, 2002 In Use
57902-0249-05 57902-0249 Asparaginase Erwinaze 10000.0 [iU]/mL Chemotherapy Miscellaneous Agent Enzyme Intramuscular, Intravenous Nov 18, 2011 Jul 23, 2021 No Longer Used
00944-3810-01 00944-3810 Pegaspargase Oncaspar 750.0 [iU]/mL Chemotherapy Miscellaneous Agent Enzyme Intramuscular, Intravenous Feb 1, 1994 May 16, 2020 No Longer Used
81561-0413-05 81561-0413 asparaginase ERWINASE 10000.0 [iU]/mL Chemotherapy Miscellaneous Agent Enzyme Intramuscular, Intravenous Jun 1, 2021 In Use
72694-0954-01 72694-0954 Pegaspargase Oncaspar 750.0 [iU]/mL Chemotherapy Miscellaneous Agent Enzyme Intramuscular, Intravenous Jan 2, 2020 In Use
70437-0240-33 70437-0240 Neratinib Nerlynx 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Jul 17, 2017 In Use
70437-0240-18 70437-0240 Neratinib Nerlynx 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Jul 17, 2017 In Use
42291-0035-15 42291-0035 Lapatinib Lapatinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Mar 12, 2025 In Use
00173-0752-00 00173-0752 Lapatinib TYKERB 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Mar 16, 2007 Nov 30, 2017 No Longer Used
68180-0801-36 68180-0801 lapatinib Lapatinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Sep 29, 2020 In Use
00480-3237-51 00480-3237 Lapatinib Lapatinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Dec 19, 2024 In Use
00078-0671-19 00078-0671 Lapatinib TYKERB 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Aug 3, 2016 In Use
70437-0240-26 70437-0240 Neratinib Nerlynx 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Jul 17, 2017 In Use
57894-0514-01 57894-0514 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) RYBREVANT FASPRO 2240.0 mg/14mL, 28000.0 mg/14mL Immunotherapy Bispecific Antibody EGFR, MET Subcutaneous Dec 17, 2025 In Use
57894-0522-01 57894-0522 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) Rybrevant Faspro 3520.0 mg/22mL, 44000.0 mg/22mL Immunotherapy Bispecific Antibody EGFR, MET Subcutaneous Feb 13, 2026 In Use
57894-0515-01 57894-0515 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) Rybrevant Faspro 2400.0 mg/15mL, 30000.0 mg/15mL Immunotherapy Bispecific Antibody EGFR, MET Subcutaneous Feb 13, 2026 In Use
57894-0510-01 57894-0510 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) RYBREVANT FASPRO 1600.0 mg/10mL, 20000.0 mg/10mL Immunotherapy Bispecific Antibody EGFR, MET Subcutaneous Dec 17, 2025 In Use
57894-0501-01 57894-0501 Amivantamab Rybrevant 350.0 mg/1 Immunotherapy Monoclonal Antibody EGFR, MET Intravenous May 21, 2021 In Use
66733-0958-23 66733-0958 Cetuximab Erbitux 2.0 mg/mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct 2, 2007 In Use
00597-0137-90 00597-0137 Afatinib Gilotrif 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct 1, 2018 May 31, 2027 In Use
59651-0530-03 59651-0530 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Jun 22, 2022 In Use
55513-0954-21 55513-0954 Panitumumab Vectibix 100.0 mg/5mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct 1, 2025 In Use
63304-0095-11 63304-0095 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov 5, 2019 In Use
46708-0566-30 46708-0566 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Jul 9, 2021 In Use

Found 12250 results — Export these results